Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer by Angela Fuchs et al.
Fuchs et al. Diagnostic Pathology 2014, 9:48
http://www.diagnosticpathology.org/content/9/1/48RESEARCH Open AccessTuberous-sclerosis complex-related cell signaling
in the pathogenesis of lung cancer
Angela Fuchs1,3*, Katharina König2, Lukas C Heukamp2, Jana Fassunke2, Jutta Kirfel3, Sebastian Huss5,
Albert J Becker4, Reinhard Büttner2 and Michael Majores3Abstract
Background: Hamartin (TSC1) and tuberin (TSC2), encoded by the tuberous sclerosis complex (TSC) genes, form a
tumor-suppressor heterodimer which is implicated in PI3K-Akt signaling and acts as a functional inhibitor of the
mammalian target of rapamycin (mTOR). Dysregulation of mTOR has been assigned to carcinogenesis and thus
may be involved in cancer development. We have addressed the role of hamartin, phospho-tuberin (p-TSC2) and
phospho-mTOR (p-mTOR) in a series of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) samples.
Methods: We collected 166 NSCLC and SCLC samples for immunohistochemical studies and performed western
blot analyses in NSCLC and SCLC cell lines as well as comparative analyses with EGFR phosphorylation and
downstream effectors.
Results: In cell lines we found an inverse correlation between hamartin and p-mTOR expression. In surgical specimens
cytoplasmic hamartin expression was observed in more than 50% of adenocarcinoma (AC) and squamous cell
carcinoma (SCC) compared to 14% of SCLC. P-mTOR and p-TSC2 staining was found in a minority of cases.
There was a significant correlation between p-EGFR Tyr-1068, p-EGFR Tyr-992 and hamartin, and also between p-mTOR
and p-EGFR Tyr-1173 in AC. In SCC an inverse correlation between hamartin and p-EGFR Tyr-992 was detected.
Phosphorylation of TSC2 was associated with expression of MAP-Kinase. Hamartin, p-TSC2 and p-mTOR expression was
not dependant of the EGFR mutation status. Hamartin expression is associated with poorer survival in SCC and SCLC.
Conclusions: Our findings confirm the inhibitory role of the tuberous sclerosis complex for mTOR activation in lung
cancer cell lines. These results reveal hamartin expression in a substantial subset of NSCLC and SCLC specimens, which
may be due to EGFR signaling but is not dependant on EGFR mutations. Our data provide evidence for a functional
role of the tuberous sclerosis complex in lung cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
9274845161175223.
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Lung cancer is one of the most common cancer diseases
and a major tumor-related cause of death in western in-
dustrialized countries, accounting for more than 1 mil-
lion new cases and deaths each year (12.6% of all new
cancers, 17.8% of cancer related deaths). According to
the WHO classification of 2004 malignant epithelial lung* Correspondence: angela.fuchs@ukb.uni-bonn.de
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unless otherwise stated.tumors are classified into main subsets based on histomor-
phologic and immunohistochemical features [1]. These
subsets comprise squamous cell, small cell, large cell, ade-
nosquamous, sarcomatoid carcinomas and adenocarcin-
omas comprising different subtypes [2,3]. Despite major
efforts in standardized diagnostic and therapeutic proce-
dures, patients’ overall survival remains poor, i.e. complete
remission and long-term survival is only rarely achieved.
A better understanding of the molecular mechanisms of
carcinogenesis and disease progression is essential for the
development of targeted therapies [4]. Growing evidence
supports the pathogenic role of abnormal EGFR-relatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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naling cascades (Figure 1). Activation of the EGFR path-
way mediated by activating mutations in its constituents is
a key driver in adenocarcinomas of the lung, mediating
important carcinogenic properties such as cell-cycle pro-
gression, apoptosis, angiogenesis and metastasis [5]. Dis-
tinct activating in EGFR and activation of associatedFigure 1 EGFR associated signaling pathways in lung cancer. Phospho
results in various downstream signaling pathways including the JAK-STAT-s
related pathway. Extrinsic binding of the Endothelian Growth Factor (EGF)
to phosphorylation of EGFR and subsequent activation of phosphatidylinos
TSC1/TSC2, diminishing its inhibitory effect on Rheb (Ras homolog enriche
TSC-complex leads to activation (disinhibition) of mTOR and may play a pu
activation; bars represent inhibitory effects.signaling pathways is a well-established finding in upto
20% of adenocarcinoma located in the lung [6,7] and
tyrosine-kinase inhibitors (TKI) directed against the EGFR
have entered clinical practice. EGFR-related downstream
effects are mediated by the phosphatidylinositol 3-kinase
(PI3K) - Akt signaling cascade, which promotes tumor cell
growth and inhibition of apoptosis by activation of mTORrylation, i.e. activation of the Epidermal Growth Factor Receptor (EGFR)
ignaling, KRAS, MAPK and the phosphatidylinositol 3-kinase (PI3K)
to the corresponding Endothelian Growth Factor Receptor (EGFR) leads
itol 3-kinase (PI3K). PI3K signaling results in an activation of Akt and
d in brain), a major activator of mTOR signaling. Disruption of the
tative pathogenic role in lung cancer pathogenesis. Arrows represent
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therefore become essential to determine therapeutic op-
tions and assess potential therapy failure due to secondary
resistance to TKI-therapy; e.g. recent mutation analysis re-
vealed a new activating mutation in Exon 19 in the EGFR
gene in a liver metastasis of a primary lung adenocarcinoma
with therapeutical potential [10]. Furthermore there are
large efforts and promising results regarding optimization
of immunohistochemical markers as prescreening tests to
detect EGFR mutations in potential TKI candidates [11].
The present study is focusing on a central regulator of
the EGFR-dependant PI3K - mTOR pathway, i.e. the tu-
berous sclerosis tumor suppressor complex (TSC). The
TSC complex is constituted by a heterodimer of hamar-
tin and tuberin, encoded by the TSC1 and TSC2 genes.
Germline mutations of the TSC1 and TSC2 genes cause
the familial syndrome of tuberous sclerosis complex [12].
Those patients suffer from hamartomas and tumors in vari-
ous tissues such as kidney angiomyolipoma, cardiac rhab-
domyoma, subependymal giant cell astrocytoma (SEGA)
and increased risk for renal cancer [13]. TSC acts via the
GAP protein Rheb (Ras homolog enhanced in brain) and
thereby leads to an inhibition of mTOR [14]. Vice versa,
disruption of the TSC tumor suppressor complex results in
an upregulation of mTOR. Moreover, mTOR signaling may
be interfered by Rapamycin, a negative regulator of mTOR
[15]. A pathogenic role of the TSC tumor-suppressor com-
plex has been described in diverse sporadic malignant neo-
plasms, such as sporadic bladder cancer, breast cancer,
ovarian carcinoma and gall bladder carcinoma [16,17]. In
lung cancer, only sparse data concerning a putative patho-
genic role of the TSC complex are available. A loss of het-
erozygosis (LOH) of the TSC1-locus on chromosome 9q34
was observed in AC and precursor lesions, i.e. atypical ad-
enomatous hyperplasia [18]. Furthermore, TSC1 mutations
and polymorphisms, but no truncating mutations were
found in AC specimens [19]. Another study reported LOH
for hamartin or TSC2 in 22% of 86 specimens, but
none of the 80 lung cancer lines studied showed lack of
expression or complete loss of either hamartin or TSC2
[20]. This is the first comprehensive immunohistochemi-
cal and clinicopathological study of the Tuberous-sclerosis




In total, 166 patient samples were included in the study
and chosen from the archival files of the Institute of
Pathology, University Bonn Medical School. Patients suf-
fered from primary malignant tumors of the lung and
were subjected to surgical resection or diagnostic sam-
pling between June 1995 and December 2006. In each
case, the primary pulmonary origin of the neoplasms wasaffirmed by a panel of immunohistochemical analyses by
experienced pathologists. The male: female ratio (109: 57),
mean age at diagnosis (64.2 years; SD +/− 9.8 years; range
33 – 86 years) and follow-up characteristics of our cohort
were in accordance with the published epidemiologic dis-
tribution and clinical course.
Tumor samples derived from formalin-fixed, paraffin-
embedded tissue. According to the current WHO classi-
fication (2004) these samples were classified in 92 AC,
31 SCC and 43 SCLC. For NSCLC specimens we created
tissue microarrays (TMAs) in paraffin embedded tissue.
NSCLC and unaffected tissue specimens were analyzed
using TMAs comprising 3 tissue samples of 1.6 mm
diameter of each case. To verify the representativeness
of TMA-immunohistochemistry, whole block sections of
44 cases randomly chosen among the malignant tissue
series were stained in parallel. Only one of 44 cases revealed
to be false-negative and vice-versa, 9 of 10 positive samples
in the whole paraffine block specimens were also found
positive in the TMA specimens. Therefore were considered
TMAs to be valid for immunohistochemical characteri-
zation of NSCLC specimens. Due to limited availability of
resected specimens, SCLC were examined by staining
whole sections of biopsied samples.
Immunohistochemistry
The classification of tumors was based on hematoxylin
and eosin staining, and ascertained by the use of primary
antibodies for the detection of TTF-1 (monoclonal, diluted
1:50, DAKO, Hamburg, Germany), CD56 (monoclonal,
diluted, 1:50, DAKO), CK5/6 (monoclonal, diluted 1:50,
DAKO), and CK7 (monoclonal, diluted 1:500, DAKO),
using standard protocols. For the present study, the fol-
lowing primary antibodies were used for immunohisto-
chemical staining: P-mTOR (Ser2448) (polyclonal, diluted
1:100, Cell Signaling, Frankfurt, Germany), hamartin/
TSC1 (1B2) (monoclonal, diluted 1:200, Cell Signaling)
and p-tuberin/TSC2 (Thr1462) (5B12) (monoclonal, di-
luted 1:100, Cell Signaling). Antibody incubation was per-
formed over night at 4°C after heat treatment of the slides
(DakoCytomation Pascal pressure chamber, 3 minutes in
0.01 M sodium citrate buffer, ph 6.0). Negative control re-
actions replacing the primary specific antibody by non-
specific immunoglobulin were performed exemplarily to
assure specific binding affinity. Endogenous peroxidase
activity was quenched by incubation with DakoReal
Peroxidase-Blocking Solution S2023 for 5 minutes. Block-
ing of nonspecific binding was performed with DakoReal
Buffer Kit K5006, containing carrier protein, detergent and
preservative. Biotinylated secondary antibody (incubation
of 30 minutes at room temperature) and Strepavidin/HRP
incubation was performed using the DakoReal Detection
System. Sections were counterstained with hematoxylin.
Additionally, we performed statistical comparisons with
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concerning signaling pathways in lung cancer pathogenesis
(p-EGFR, Stat3, Akt) [21]. Immunostaining was analysed
semiquantitatively in a four-tiered scoring approach, assign-
ing TMA samples to 0) negative, 1) equivocal, 2) weak to
moderate, and 3) strong. Statistical analysis was performed
using a Fischer’s exact test.
Cell culture
In this work 5 cell lines of SCLC and NSCLC were exam-
ined. All cell lines were cultured in an incubator at 37°C
and 5% CO2 in 75 cm2 tissue culture flasks (CORNING,
Kaiserslautern, Germany) containing 15 ml of sterile
medium. The following cell lines were used: “NCI-H460”,
a human large cell lung carcinoma cell line bearing a
K-Ras G61 H mutation; “MBA 9812 16B13”, a squamous
cell carcinoma cell line; “HCC827”, an adenocarcinoma
cell line harboring an acquired mutation within the EGFR
tyrosine kinase domain (E746-A750 deletion). SCLC cell
lines: “GLC-2” and “GLC-8”. The cell lines NCI-H460,
GLC-2 and MBA-9812-16B13 were routinely cultured in
RPMI 1640 medium (Invitrogen, Karlsruhe, Germany)
supplemented with 8% fetal bovine serum (Invitrogen),
L-glutamine (GIBCO), 1 mmol Sodium-Pyruvate (Invitro-
gen), penicillin/streptomycin (PAA, Cölbe, Germany), and
β-mercaptoethanol (Merck). GLC-8 and HCC827 were
cultured in IMDM (PAA) supplemented with additions as
above. Growth media were changed at least after 48–72 h.
Western blot analyses
Protein isolation was performed by harvesting 5 × 106 cells
and centrifugation at 3000 rpm and 4°C for 3 minutes. The
pellet was dissolved in 100 μl RIPA- Buffer (SIGMA-
ALDRICH, Germany) and incubated on ice for 30 mi-
nutes. Centrifugation at 13000 rpm and 4°C for 15 minutes
finally enabled to take the supernatant which contained
the proteins. The extracted protein concentrations were
measured according to the method of Bradford. Protein
lysates from 50000 cells were supplemented with NuPage
LDS Sample Buffer (4 ×) (Invitrogen), NuPage Sample
Reducing Agent (10 ×) (Invitrogen), PBS (PAA) and dena-
turized at 95°C for 5 minutes. Proteins were loaded on
NuPage 4-12% Bis-Tris Gel (1.5 mm × 15 well, Invitrogen),
placed in Xcell Sure Lock Mini-Cell device (Invitrogen),
filled with MOPS SDS Running buffer (Invitrogen) and
separated at 170 V for 1 h30. Magic Mark XP Western
Standard (Invitrogen) for hamartin/TSC1 and HiMark Pre-
Stained High Molecular Weight Protein Standard (Invitro-
gen) for P-mTOR and P-tuberin/TSC2 were used to make
protein sizes comparable. Proteins were transferred to a
nitrocellulose membrane using Xcell II Blot Module (Invi-
trogen) filled with NuPage Transfer Buffer without metha-
nol at 30 V for 1 h40. After blocking in 5% nonfat drymilk/
TBST (Tris-buffered saline solution containing 0.1% Tween20) for 1 hour at room temperature the membranes were
incubated with a polyclonal rabbit primary anti-p-mTOR
(Ser2448) and anti-p-tuberin /TSC2 (Thr1462) (5B12)
antibody (Cell Signaling) as well as a monoclonal mouse
anti-hamartin/TSC1 antibody (1B2) (Cell Signaling) in
5% nonfat drymilk/TBST at a dilution of 1:1000 over
night at 4°C in 5% BSA/TBST. Next to that they were
washed 3 times for 10 min each and incubated with
HRP-Goat Anti-Rabbit IgG secondary antibody (Zymed,
Invitrogen) for p-mTOR (Ser2448) and p-tuberin /TSC2
(Thr1462) (5B12) at a dilution of 1:4000 in 5% nonfat
drymilk/TBST for 1 hour at room temperature meanwhile
hamartin/TSC1 (1B2) was incubated with HRP-Goat
Anti-Mouse secondary antibody (SIGMA-ALDRICH) at a
dilution of 1:2000 in 5% nonfat drymilk/TBST. Immuno-
reactive proteins were visualized with 0.125 ml/cm2 ECL
Western blotting detection reagents and analysis system
(GE Healthcare, Amersham).
DNA extraction, polymerase chain reaction (PCR) and
DNA sequencing
DNA was isolated from the cultured cell lines (n = 5) and
1 blood sample arising from a healthy person as additional
control. DNA was isolated and purified using a QIAamp
DNA Mini Kit (QIAGEN, Germany) according to the
manufacturer’s instructions for cultured cells or rather
whole blood. Amplification was performed in a 25 μl reac-
tion mixture containing 20 ng DNA, 0.2 mM of each
dNTP, 0.2 μl Taq DNA polymerase (Invitrogen, 5 U/μl),
2.5 μl 10 × Buffer, 1 μl of 50 mM MgCl2, 200 μM primer
(forward and reverse) and appropriate volume of sterile
water. Primer sequences and combinations for TSC1 were
used as described elsewhere in detail [22]. The parameter
for amplification of TSC1 was predenaturating at 95°C for
5 min followed by 35 cycles at 95°C for 1 min, annealing
at 55°C for 1 min and 72°C for 1 min and a final extension
at 72°C for 7 min in an automated thermocycler (MJ
Research PTC-200 Thermo Cycler). After PCR amplifica-
tion 2 μl of each product supplemented with loading buffer
(Invitrogen) and a marker (100 bp Molecular Ruler, BIO-
RAD) were electrophoresed in 2.5% agarose gel, stained
with ethidium bromide (Invitrogen) and then photographed
under ultraviolet (UV) light. The comparison of marker
and size of the amplification product ensured the presence
of the wanted DNA section.
For DNA sequencing, excess primers and residuals were
removed from the remaining PCR Product by PEG precipi-
tation as described elsewhere in detail [23] and PCR prod-
ucts were dissolved in a final volume of 20 μl. DNA was
quantified by measuring the UV absorption and the quality
was examined by electrophoresis. The extended fragments
were sequenced with the BigDye® Terminator v1.1 Cycle
Sequencing Kit (applied Biosystems, Germany) according
to the manufacturer’s instructions in the ABI PRISM® 310
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lysed by comparison with the GenBank sequence file.
Statistical analyses
Expression data of both whole block sections and TMA
sections were subjected to statistical analyses. Associations
between immunohistochemical expression, the clinical fol-
low up and preliminary data concerning EGFR mutations
were tested by Pearson’s 2-sided Χ2 test. Correlation coeffi-
cients for immunohistochemical correlations were esti-
mated by Kendall's rank correlation. All cutoff values of
significance were set p < 0.05 with 2-sided testing. Survival
proportions were assessed using the Kaplan-Meier method
(IBM SPSS Statistics 20).
Results
Inverse correlation of hamartin and p-mTOR expression in
human lung cancer cell lines
We performed western blot analyses using cultured cells of
SCLC (cell lines: GLC-2 and GLC-8) and NSCLC (cell
lines: NCI-H460, MBA 9812, HCC-827). We found hamar-
tin, p-tuberin and p-mTOR protein expression by western
blot in all cell lines. GLC-8, MBA 9812 and HCC-827
cells showed an inverse correlation between hamartin
and p-mTOR expression. Higher hamartin levels were
associated with low levels of p-mTOR and, vice versa a
substantial expression of p-mTOR was obtained in associ-
ation with decreased levels of hamartin. No correlation
between p-tuberin and hamartin or p-mTOR was found
(Figure 2).
Immunohistochemical analysis of hamartin, p-tuberin
and p-mTOR: hamartin is expressed in a large proportion
of cases
Cytoplasmic hamartin staining was found in a substantial
proportion of AC revealing a strong cytoplasmic expressionFigure 2 Western blot analysis for p-mTOR, TSC1 and p-tuberin (Thr1
cells, we found an inverse correlation between hamartin and p-mTOR concen
and, vice versa a substantial expression of p-mTOR was obtained in associatio
between p-tuberin levels with those of hamartin or p-mTOR. NCI-H460: large c
mutation in the EGFR tyrosine kinase domain (E746 - A750 deletion), GLC-2 anin 40.2% and a moderate expression in additional 18.5%.
SCC also revealed hamartin in slightly more than 50%
(strong expression in 29% and moderate expression in
25.8%). In contrast, only 14% of SCLC expressed hamartin
(strong expression in 9.3% and moderate expression in an-
other 4.7%). P-mTOR expression was found either in the
cytoplasm or in nuclear position. Nuclear staining was
found in 22.8% of AC (strong labeling in 4.3% and moder-
ate staining in 18.5%) and in 35.5% of SCC (strong expres-
sion in 6.5% and moderate expression in 29%). SCLC less
frequently expressed p-mTOR in the nucleus (4.7% strong /
11.6% moderate). Cytoplasmic labeling of p-mTOR was
found in 21.8% of AC (strong labeling in 3.3% and moder-
ate staining in 18.5%), 9,7% in SCC (0% strong / 9.7% mod-
erate expression), but was not detected in SCLC specimens.
Cytoplasmic p-TSC2 expression was found in 16.3% of AC
(moderate to strong staining) compared to moderate ex-
pression in 6.5% of SCC resp. 4.7% of SCLC (Figure 3).
In non-neoplastic control tissue, hamartin was expressed
in bronchus epithelia with accumulation in the apical sub-
membranous compartments of the cells. It was not detect-
able in the alveolar epithelial cells. P-mTOR and p-tuberin
were not detected in bronchiolar or alveolar epithelial cells
immunohistochemical (Figure 3).
Furthermore, we screened for correlations between
hamartin, p-mTOR and p-TSC2. A significant correlation
between the expression of p-TSC2 and p-mTOR was found
in AC specimens (p-TSC2 vs. nuclear p-mTOR: correlation
coefficient (CC) = 0.305; p = 0.004; p-TSC2 vs. cytoplasmic
p-mTOR: CC = 0.303; p = 0.016) and in SCLC speci-
mens (p-TSC2 vs. nuclear p-mTOR: CC = 0.409; p = 0.006;
pTSC2 vs. cytoplasmic p-mTOR: CC = 0.422; p = 0.005). In
SCLC, the expression of hamartin correlated with that of
p-TSC2 (CC = 0.669; p < 0.001) and with the expression of
nuclear p-mTOR (CC = 0.405; p = 0.007). In SCC patients
no significant correlations were revealed.462) in NSCLC and SCLC cell lines. In GLC-8, MBA 9812 and HCC-827
trations. Higher TSC1 levels were associated with low levels of p-mTOR
n with decreased levels of TSC1. There was no obvious correlation
ell cancer of the lung, MBA 9812: SCC, HCC-827: AC harboring an acquired
d GLC-8: SCLC.
Figure 3 Immunohistochemistry. In normal tissue, only TSC1 is expressed in bronchus epithelia but not in alveolar surface cells (A). P-mTOR
and p-tuberin were not detected in normal tissue (B, C). TSC1 was expressed in more than 50% of AC (D) and SCC (G) in contrast to 14% of SCLC
(J). P-TSC2 was weakly expressed in 16.3% of AC (E), 6.5% of SCC (H) and 4.7% of SCLC (K). P-mTOR expression was found either in the cytoplasm
or in nuclear position (F, I, L). Nuclear p-mTOR staining was found in 22.8% of AC (F), 35.5% of SCC (I) and 16.3% of SCLC (L). Cytoplasmic labeling of
p-mTOR was found in 21.8% of AC (F) and 9.7% of SCC (I), but not in SCLC (L) specimens. Figures A-C: normal lung, D-F: AC, G-I: SCC, J-L: SCLC.
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upstream of TSC-mTOR reveals a substantial co-expression
of hamartin and phosphorylated EGFR at position Tyr-1068
as well as with p-EGFR at position Tyr-992
We correlated the expression of hamartin, p-TSC2 and
p-mTOR with expression data concerning epidermal
growth factor receptor mutations in non-small cell lung
cancer and their influence on downstream Akt, MAPK
and Stat3 signaling [21]. In AC specimens, we found asubstantial co-expression of hamartin and phosphory-
lated EGFR at position Tyr-1068 (CC = 0.472; p = 0.001)
as well as with p-EGFR at position Tyr-992 (CC = 0.706;
p < 0.001). Phosphorylation of mTOR was closely correlated
with p-EGFR Tyr-1173 (CC = 0.643; p < 0.001) (Table 1). In
SCC specimens, an inverse correlation was found between
hamartin and p-EGFR Tyr-992 (CC =−0.688; p = 0.001).
Furthermore, p-TSC2 was inversely correlated with expres-
sion of MAP-Kinase (CC = −0.708; p = 0.003).
Table 1 Correlation of hamartin and p-mTOR with
expression data concerning phosphorylated epidermal
growth factor receptor in adenocarcinoma
EGFR mutation Test Hamartin P-mTOR
Phospho-EGFR Tyr-992 Pearson correlation - 0,052 0,404b
Sig. (2-tailed) 0,728 0,027
N 47 30
Phospho-EGFR Tyr-1173 Pearson correlation 0,027 0,643a
Sig. (2-tailed) 0,859 < 0,001
N 46 30
aCorrelation is significant at the 0.01 level (2-tailed).
bCorrelation is significant at the 0.05 level (2-tailed).
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sequence alteration in exon 23
We considered whether accumulation of hamartin was due
to TSC1 sequence alterations. Sequence alterations of
TSC1 were found in only one cell line, i.e. the “HCC827”
cells, i.e. an adenocarcinoma cell line harboring an acquired
mutation within the EGFR tyrosine kinase domain. We
only detected one sequence alteration in exon 23 with mul-
tiple base pair transitions leading to a complex alteration
of the amino acid composition, but without truncation of
the protein.
P-mTOR expression tended to be more frequently among
EGFR + cases when correlating immunohistochemical data
with EGFR mutation status
We then wondered whether expression of hamartin, p-
mTOR or p-TSC2 was associated with EGFR-mutations
since approximately 20% of adenocarcinoma of the lung
patients’ specimens reveal EGFR-mutations [24]. To ad-
dress this issue, we analysed 12 cases with established
EGFR mutation status for therapeutic purposes (each 6
cases with/without EGFR mutations) and evaluated the
tumor specimens for hamartin, p-tuberin and p-mTOR
expression. For hamartin 2 of 6 tumors harboring EGFR
mutations (EGFR+) showed an expression level >2, com-
pared to 1 case in the group of EGFR wild-type tumors
(EGFR-) showing an expression level >2. For p-tuberin,
in each group (EGFR+ / EGFR-) only one case showed an
expression level 1. Four of six EGFR + tumors weakly
expressed p-mTOR compared to two of six cases without
mutated EGFR. P-mTOR expression tended to be more
frequently among EGFR + cases. Concerning hamartin and
p-tuberin, there was no obvious association to the EGFR
mutation status (Table 2).
The clinical follow-up shows that hamartin staining is
associated with poorer survival in a subset of lung
cancer entities
Overall, follow up data were available in 98 of 166 cases
(59.0%). 76 of 98 patients died within the follow upperiod (77.5%). The remaining 22 patients were docu-
mented as ’still alive’ at the last available time point.
Only in six patients without documentation of death the
follow-up period was less than 60 months. The median
survival of AC cases was 51 months (SD 9.7; 95% CI:
31.9 – 70.0; n = 56), compared to SCC with 15 months
(SD 8.2; 95% CI: 0 – 31.1; n = 17), and SCLC with
5 months (SD 1.9; 95% CI: 1.2 – 8.8; n = 24). As expected,
the histological tumor type (AC vs. SCC vs. SCLC) influ-
enced the overall survival characteristics, in accordance
with published clinicopathological data for lung cancer
[1,25]. It should be noted that AC and SCC patients in-
cluded in the present study were treated with a curative
aim, whereas the collective of SCLC patients represent
cases with both curative and palliative regimens. More-
over, survival was dependant on the extent of the tumor
(pT) as well as the lymphonodular spread (pN) (Figure 4).
Based on the four-tiered semiquantitative expression
analysis, immunohistochemical hamartin staining was
significantly associated with a poorer survival in SCC and
SCLC patients (Figure 4). In SCC specimens with moder-
ate resp. strong hamartin expression survival was signifi-
cantly poorer (mean survival 2.25 resp. 21.75 months)
compared to cases with no expression or equivocal stain-
ing characteristics (mean survival 50.0 resp. 56.4 months)
(p = 0.014). The same negative prognostic effect was found
in SCLC cases (mean survival of 0.5 resp. 1 month in
SCLC specimens with moderate resp. strong hamartin
expression vs. 11.2 resp. 4.1 months in cases with no
expression or equivocal staining) (p < 0.01). For AC speci-
mens the Kaplan-Maier plot revealed no effect of hamar-
tin expression on survival (mean survival of 93.9 resp.
71.9 months for moderate resp. strong hamartin expres-
sion vs. 90.3 resp. 16.5 months in cases with no expression
or equivocal staining) (Figure 4).
Expression of cytoplasmic or nuclear p-mTOR as well
as expression of p-TSC2 did not influence survival pro-
portions (all p > 0.05).
Discussion
In the present study we examined the morphological
characteristics and functional role of the TSC tumor
suppressor complex as a major regulator of mTOR ac-
tivity. We could show that the TSC tumor suppressor
complex is substantially expressed in lung cancer cell
lines and that hamartin and p-mTOR were inversely corre-
lated in three of the five lung cancer cell lines. Further-
more, slightly more than 50% of the NSCLC specimens
showed hamartin expression, compared to nearly one third
of SCLC with valuable hamartin expression. These findings
demonstrate that hamartin expression is a frequent finding
in lung cancer. A major challenge is to assess whether ac-
cumulation or loss of hamartin (and p-tuberin) reflects pri-
mary or secondary events. Both, accumulation or loss of
Table 2 Staining of AC with established EGFR mutation status
EGFR sequence alterations Immunohistochemical analysis
No. EGFR mutation Mutation Exon TSC1 P-TSC2 P-mTOR
1 Yes c.2573 T > G; p.L858R 21 — — —
2 Yes p.E746_P753 delinsIS c.2236_2259(24 bp)delinsATCTCG 19 + + +
3 Yes c.2236_2250del p.E746_A750del 19 — — —
4 Yes p.L858R c.2573 T > G 21 — — +
5 Yes c.2235_2249del p.E746_A750del 19 — — +
6 Yes p.L858R 21 + — +
7 No Wild type — — —
8 No Wild type + — —
9 No Wild type — — —
10 No Wild type — — +
11 No Wild type — + +
12 No Wild type — — —
Figure 4 Kaplan-Meier curves for different tumor types. The clinical course (overall survival) (OS) was dependant on the tumor type (AC vs.
SCC vs. SCLC) (A), the extent of the tumor (pT) (B) as well as the extent of lymphonodular spread (pN) (C), indicating a representative tumor
cohort in the present study. In SCC and SCLC specimens, moderate resp. strong hamartin expression survival was significantly poorer compared
to cases with no expression or equivocal staining characteristics (p = 0.014 resp. p < 0.01) (E, F). This effect was not obtained for AC specimens
(p > 0.05) (D). n: negative, e: equivocal, m: moderate, s: strong hamartin expression.
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http://www.diagnosticpathology.org/content/9/1/48hamartin, could be pathogenically relevant for carcinogen-
esis. As in normal tissue hamartin is only expressed in
bronchial respiratory epithelia but not in alveolar epithelial
cells, we cannot conclude if hamartin expression reflects a
gain or loss of function in tumor specimens. In NSCLC
and SCLC cell lines, high protein levels of hamartin were
associated with low p-mTOR and vice versa. This inverse
correlation between hamartin and mTOR levels supports
an interaction between TSC and mTOR in NSCLC and
SCLC. All cell lines used for the present study revealed de-
tectable hamartin and p-TSC2 protein levels indicating that
expression differences are rather due to a loss of hamartin
expression. This interpretation is also reasonable in the
light of previous studies showing a loss of heterozygosity
(LOH) of the TSC1-locus on chromosome 9q34 in AC and
precursor lesions [18]. Another study also reported LOH
for hamartin or TSC2 in 22% of 86 specimens, but none of
the 80 lung cancer lines studied [20].
In SCLC, we found that hamartin expression correlates
with p-TSC2 and may point towards a disruption of the
hamartin-tuberin complex, which is accompanied by
phosphorylation of tuberin and activation (i.e. phosphor-
ylation) of mTOR. Moreover, the expression of hamartin
correlated with that of nuclear p-mTOR (CC = 0.405;
p = 0.007) suggesting that hamartin may be an interesting
surrogate marker for mTOR related signaling. The immu-
nohistochemical characterization of signaling pathways dur-
ing the routine histological workup of specimens would
greatly facilitate the selection of individualized therapeutic
regimens that are currently arising by the availability of
new molecular targets such as mTOR inhibitors [26].
Growing evidence supports abnormally activated mTOR
to play an important pathogenic role in lung cancer associ-
ated with both KRAS and EGFR mutations and may pro-
vide a mechanism of resistance to treatment with EGFR
inhibitors [26,27]. The EGFR can be autophosphorylated
on various tyrosine sites and distinct downstream signaling
cascades are initiated by the EGFR depending on its phos-
phorylation pattern [28,29]. As EGFR signaling is partially
mediated via KRAS and both KRAS and EGFR can activate
PI3K, a potential link with TSC is reasonable (Figure 1). A
potential interaction between TSC and KRAS has been
postulated in mice [20]. Tumors of animals harboring
hamartin loss and KRAS (G12D) expression in lung epi-
thelial cells revealed 1) reduced tumor latency, 2) an ac-
tivation of mTOR and 3) a response to treatment with
rapamycin with improved survival compared to KRAS
alone mutant mice [20]. These observations suggest that
the TSC complex may be a critical regulator of KRAS-
related signaling cascades that are focusing on mTOR.
Overall, these data support a rather complex, interdepend-
ent regulation of the TSC complex and the EGFR/KRAS
signaling. We have therefore used immunohistochemical
data of a recent study and speculated if abnormal activationof mTOR is due to pathogenic events upstream of the
hamartin-tuberin-complex. Based on this approach, we
found a significant correlation between hamartin and
p-EGFR (Tyr-1068) resp. p-EGFR (Tyr-992) expression
in AC specimens [21]. P-mTOR was also closely corre-
lated with p-EGFR Tyr-1173. These findings indicate
that expression or even accumulation of hamartin may
also be secondary to EGFR phosphorylation. In con-
trast, an inverse correlation was found between hamartin
and p-EGFR Tyr-992 in SCC specimens indicating differ-
ent molecular fingerprints in different cancer subtypes.
We have also hypothesized that hamartin, p-tuberin
and p-mTOR expression may be dependant of the EGFR
mutation status. In 12 cases with already established EGFR
mutation status for therapeutic purposes, hamartin accu-
mulation was found both in EGFR-mutated and EGFR wild
type tumors (Table 2). Also p-tuberin expression was de-
tected both in EGFR + and EGFR- cases. Nuclear expres-
sion of p-mTOR was slightly more frequent in patients
harboring EGFR mutations, however it was also detectable
in EGFR-wild type cases. Therefore, we conclude that the
EGFR mutation status does not affect expression of hamar-
tin, p-tuberin and p-mTOR responsive to EGFR mutations.
This assumption is also supported by the observation that
phosphorylation of tyrosine residues 922 and 1173, but not
phosphorylation of tyrosine residues 1068, have been asso-
ciated with activating EGFR mutations [21].
We have also raised the question, if accumulation of
hamartin may be secondary to mutational alterations.
Notably, LOH for the TSC1 or TSC2 locus has been de-
scribed in 22% of 86 human lung cancer specimens [20].
In another study more than one third of atypical adenoma-
tous hyperplasia precursor lesions and 53% of concomitant
adenocarcinomas displayed LOH on 9q. A substantial pro-
portion of these harbored LOH at loci adjacent to the
TSC1 gene [18]. However, only one cell lines used in the
present study revealed a TSC1 sequence alteration, i.e.
the HCC-827 cell line (AC harboring an acquired muta-
tion in the EGFR tyrosine kinase domain). This sequence
alteration was represented by complex alterations in the
close vicinity of the stop codon in exon 23 of TSC1. We
suggest that this alteration is not functionally relevant as it
is located beyond the critical tuberin interaction domain
and as it does not result in a truncation of the protein.
Regardless of its possible pathogenic role, hamartin ex-
pression may provide as a prognostic marker. Clinical
follow up data were available in nearly two third of the
cases. As expected the histological tumor type strongly
influenced the survival rates. The longest mean survival
was observed in AC patients and the shortest in SCLC
patients. Regarding TSC-related expression, SCC and SCLC
patients revealed a poorer overall survival in hamartin posi-
tive cases. In contrast, no prognostic effect of hamartin ex-
pression could be observed for AC specimens. Differences
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molecular pathways involved during carcinogenesis resp.
therapeutic strategies. Nevertheless, other independent
factors with a potential influence on survival that have re-
cently been discussed could be considered, e.g. an overex-
pression of MTA3 gene in NSCLC as a risk factor on
survival [30] or an overexpression of IMP3 as a predictor
of aggressive tumor behavior [31]. Further investigations
in this direction should follow.
In contrast, we could not reveal a prognostic influence
of p-tuberin and p-mTOR. In another study focusing on
NSCLC, positive cytoplasmic mTOR staining was associ-
ated with shorter survival [32]. Furthermore, high mTOR
expression has been claimed to be associated with a worse
outcome in laryngeal squamous cell carcinomas that have
been subjected to postoperative radiotherapy [33]. The
discrepancy between our results and the aforementioned
studies may be due to the fact, that we recruited an anti-
body directed only against phosphorylated (i.e. activated)
mTOR, implicating a limited comparability of these re-
sults. Furthermore, we have observed p-mTOR expression
both in the cytoplasm and nucleus and the functional rele-
vance of nuclear mTOR has yet to be elucidated. Classic-
ally, mTOR acts in the cytoplasm, but recent findings
have supported compartment-specific mTOR functions in
other subcellular compartments including the nucleus
[34]. The existence of a nuclear shuttling signal in mTOR
has been postulated being essential for nuclear mTOR im-
port [35]. These findings fit well with our observations
that p-mTOR was detected not only in the cytoplasm but
also in the nucleus of tumor cells in immunohistochemical
observations. Nuclear p-mTOR staining was found in
22.8% of AC, 35.5% of SCC and 16.3% of SCLC specimens.
Thus, the different staining frequencies in the different
tumor types may also reflect the compartment-dependant
diversity of mTOR signaling. P-mTOR has also been
assigned to aggressive histological variants of papillary thy-
roid carcinoma and, thus nuclear labeling of p-mTOR has
been discussed to serve as a diagnostic and prognostic
marker as well as a potential therapeutic target [36].
Conclusions
In Summary, our results indicate hamartin, p-tuberin and
p-mTOR expression in a substantial subset of NSCLC and
SCLC specimens. We hypothesize a relevant regulation of
mTOR by the TSC complex in NSCLC and SCLC cells.
Our results support TSC activation corresponding to EGFR
and MAPK signaling, but there is no established association
with distinct EGFR mutations. Finally, our findings support
hamartin expression as a negative prognostic marker in
SCC and SCLC cases.
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